Price Alert

C4 Therapeutics Inc. (CCCC)

NASDAQ: CCCC · Real-Time Price · USD

2.44

0.09 (3.83%)

At close: Aug 15, 2025, 11:25 AM

3.83% (1D)

Bid	2.43
Market Cap	173.3M
Revenue (ttm)	27.78M
Net Income (ttm)	-111.58M
EPS (ttm)	-1.59
PE Ratio (ttm)	-1.53
Forward PE	n/a
Analyst	Hold

Ask	2.44
Volume	369,784
Avg. Volume (20D)	1,486,220
Open	2.35
Previous Close	2.35
Day's Range	2.35 - 2.48
52-Week Range	1.08 - 7.22
Beta	2.98

About CCCC

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CCCC

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CCCC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

C4 Therapeutics has released their quartely earnings on Aug 7, 2025:

Revenue of $6.46M misses estimates by $67K, with -46.17% YoY decline.

EPS of -0.37 exceeds estimates by 0.01, with -42.31% YoY decline.

Next Earnings Release

C4 Therapeutics Inc. is scheduled to release its earnings on Oct 30, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

+31.63%

C4 Therapeutics shares are trading higher after th... Unlock content with Pro Subscription

11 months ago

+13.79%

C4 Therapeutics shares are trading higher after the company announced it has delivered a second development candidate to Biogen and earned an $8 million milestone payment.

News

1 week ago · zacks.com

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Misses Revenue Estimates

C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.26 per share a year ago.

2 months ago · seekingalpha.com

C4 Therapeutics: An Entry Point If There's Ever Going To Be One

CCCC's valuation is unjustifiably low, trading at half its liquidity despite a promising pipeline and no imminent cash crisis. Lead candidate cemsidomide shows encouraging early efficacy and tolerabil...